BPH With Symptomatic Lower Urinary Tract SymptomsProVIDENCT05186740

ProVee Urethral Expander System IDE Study (ProVIDE)

A study testing ProVee Urethral Expander System and Urethral Access Sheath in people with BPH With Symptomatic Lower Urinary Tract Symptoms, run by ProVerum Medical at 16 sites in 3 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia (BPH). Read more about this study

Who is it for?: Ages 45 years and older, men onlyHealthy volunteers can take part
Conditions the study is for: BPH With Symptomatic Lower Urinary Tract Symptoms
What is being tested?: ProVee Urethral Expander System and Urethral Access Sheath
Type of treatment: Medical device, Surgery or procedure
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 221 participants
Where: 16 sitesin 3 countries
Study dates: 9 Jun 2022to Dec 2028
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 45 years and older
Men only
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Males > 45 years of age
IPSS of ≥ 13, IPSS V/S > 1 at baseline assessment
Prostate volume of ≥ 30 cc and ≤ 80 cc
Prostatic urethral L2 lengths ≥ 3.75cm by TRUS
Failed, intolerant, or subject choice to not take a medication regimen for the treatment of LUTS

Who cannot join

Void volume <125 ml; Qmax > 12ml/s; PVR > 250 ml
Obstructive median lobe defined by EITHER (>10mm protrusion on sagittal mid-prostate plane as measured by TRUS) OR an obstructive median lobe seen on cystoscopy e.g., 'ball valve''
High bladder neck, with the absence of lateral lobe encroachment indicating a high likelihood of primary bladder neck obstruction
Anatomy that would prevent the apices of the ProVee from engaging with the lateral lobes e.g., high degree of bladder neck angulation such that the anterior bladder neck is not visible
Acute urinary retention
Known immunosuppression

Show all 44Show fewer

History of or suspected prostate or bladder cancer
Baseline PSA > 10 ng/mL or confirmed or suspected prostate cancer (Subjects with a PSA level above 2.5 ng/mL, or age specific, or local reference ranges should have prostate cancer excluded to the Investigator's satisfaction, including a SOC biopsy if indicated).
Recent urinary tract stones, OR widespread calcifications on the prostatic urethral wall, within 3 months of index procedure
A history of prostatitis within the last two years
Active or history of epididymitis within the past 3 months
Neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes'
History of urinary retention within 12 months of baseline assessment
Requiring self-catheterization to void
An active urinary tract infection (UTI) at time of index procedure
Gross haematuria, within 3 months of index procedure
Subjects with known allergy to nickel or titanium
Life expectancy estimated to be less than 60 months
Taking androgens, unless eugonadal state for at least 3 months or greater with a stable dosage for at least 2 months as documented by the Investigator
Use of 5-alpha-reductase inhibitors (e.g., dutasteride, finasteride) within 6 months of baseline assessment
Use of Phenylephrine / Pseudoephedrine within 24 hours of baseline assessment
Use of alpha-blockers (e.g., Terazosin, Doxazosin, Alfuzosin, Tamsulosin) within 2 weeks of baseline assessment
Use of estrogen or drug-producing androgen suppression (e.g. gonadotropin-releasing hormonal analogues) within 1 year of baseline assessment
Use of antihistamines, anticonvulsants, and antispasmodics within 1 week of baseline assessment unless there is documented evidence that the patient was on the same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued for entrance into or throughout the study)
Use of anticholinergics or cholinergic medication within 2 weeks of baseline assessment
Use of beta-blockers where the dose is not stable. (Stable dose is defined as having the same medication and dose in the last 6 months)
Use of Phosphodiesterase-5 Enzyme Inhibitors in doses for BPH within 2 weeks of baseline assessment
Current treatment with anticoagulants (e.g., warfarin or enoxaparin) or antiplatelet medications other than aspirin (e.g., clopidogrel, or alternative and ASA). Patient unable to stop taking antiplatelet and/or antiplatelets within 3 days prior to the procedure or warfarin at least 5 days prior to the procedure. Low dose aspirin ≤100mg/day not prohibited
Future fertility concerns
Previous prostate surgery, balloon dilatation, stent implantation, laser prostatectomy, hyperthermia, or any other invasive treatment to the prostate; including penile implants
Previous pelvic irradiation or radical pelvic surgery
Previous rectal surgery (other than hemorrhoidectomy) or known history of rectal disease
Urethral strictures, bladder neck contracture, or other potentially confounding bladder pathology
Urethral pathologies that may prevent insertion of Delivery System
Uncontrolled diabetes mellitus including Hgb AIC >8%
Overactive bladder (OAB) requiring treatment by OAB medication
Urinary incontinence
Patients taking tri-cyclic antidepressants.
Compromised renal function (i.e., serum creatinine >1.8 mg/dl or upper tract disease)
Hepatic disorder, bleeding disorders or metabolic impairment that might confound the results of the study or have a risk to subject per investigator's opinion
Any major comorbidities or presence of unstable conditions, e.g., uncontrolled HTN, NYHA Class III or IV, cardiac arrhythmias that are not controlled by medication/medical device, myocardial infarction within the past 6 months, COPD with FEV1 <50, renal illness that might prevent study completion or would confound study results
Vulnerable populations such as incarcerated or institutionalized adults, inmates, patients with physical, psychological (such as developmentally delayed adults), or medical impairment that might, in the judgment of the Investigator, prevent study completion or comprehension, or may confound study results (including patient questionnaires)
History or current medical condition that would result in an unacceptable patient risk if that subject were to be included in the study
Any subject that is currently enrolled in another ongoing investigational study.

Trial locations and contacts

16 sites in 3 countries.

Country

City, postcode or hospital

16 sites in 3 countries

United States14 sites

Midtown Urology Assoc.
Austin, Texas, 78705
Urology Austin
Austin, Texas, 78745
Urological Research Network Corp
Hialeah, Florida, 33016
Houston Methodist
Houston, Texas, 77030
Comprehensive Urologic Care
Lake Barrington, Illinois, 60010
Sheldon Freedman MD
Las Vegas, Nevada, 89144
Mount Sinai
New York, New York, 10011
Advanced Urology Institute
Palm Coast, Florida, 32164
Associated Urologists of North Carolina
Raleigh, North Carolina, 27612
Golden State Urology
Sacramento, California, 95823
Southern Illinois University School of Medicine
Springfield, Illinois, 62702
Tampa Urology LLC
Tampa, Florida, 33606
Urology of Virginia
Virginia Beach, Virginia, 23462
Avant Concierge Urology
Winter Garden, Florida, 34787

Other trials in United States

Canada1 site

University Health Network
Toronto, Ontario, M5T 2S8

Other trials in Canada

Ireland1 site

St James's Hospital
Dublin

Other trials in Ireland

About this study

Official title: The ProVee Urethral Expander System Clinical Study

Read the detailed description

This is a prospective, multi-center, randomized, single-blind, sham-controlled study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia (BPH). Subjects are assigned to their treatment arm using an unbalanced (2 ProVee:1 Sham) randomization stratified by Investigational Sites.

Conditions: BPH With Symptomatic Lower Urinary Tract Symptoms
Being tested: ProVee Urethral Expander System, Urethral Access Sheath
Keywords: BPH / LUTS
Medical subject headings: Prostatic Hyperplasia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

ProVee Urethral Expander SystemDevice
Also called ProVee Expander, ProVee
ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
Urethral Access SheathProcedure or surgery
The Urethral Access Sheath is introduced into the prostatic urethra to simulate the placement of the ProVee Expander.

Study groups in NCT05186740
Study group	Role	What they receive
Device: The ProVee Urethral Expander System	Active comparator	The ProVee Urethral Expander System consists of two components: a nitinol Expander implant and a 19Fr Delivery System designed to allow the Expander to be deployed under direct vision for the treatment arm. Receives: Device: ProVee Urethral Expander System
Sham: Ureteroscope and urethral access sheath	Sham comparator	An ureteroscope housed within the inner lumen of an urethral access sheath will be used under direct vision for the Sham procedure. Receives: Procedure: Urethral Access Sheath
Crossover ProVee Urethral Expander System	Other	All subjects shall be unblinded following the 3 month follow-up visit. Those subjects randomized to the Sham Arm will be given the opportunity to "crossover" to the ProVee Urethral Expander System. Receives: Device: ProVee Urethral Expander System

What is being measured

The primary outcome is the main question the study is designed to answer.

Safety: Adverse Events (Time Frame: Procedure to 12 Months)
This includes the rate of device or procedure related serious adverse events through 12-months.
Measured: Procedure - 12 months
Safety: Number of Participants With Need for Urinary Catheterization (Time Frame: >7 Days Post Procedure)
The rate of extended post-operative urinary catheterization for inability to void among patients treated with the ProVee device.
Measured: 7 days post treatment through to 12 months
Effectiveness: Number of Participants With Reduction in BPH Symptoms Compared to Sham (Time Frame: Procedure to 3 Months)
The ProVee Treatment Group will be considered superior to the Sham Treatment Group when the mean 3-month improvement from baseline score for the IPSS symptom questionnaire demonstrates a minimum statistical margin of 25% compared to mean improvement from baseline for the Sham Treatment Group alone.
Measured: Procedure to 3 months
Effectiveness: Number of Participants With Symptoms Improvements (Time Frame: Procedure to 12 Months)
The mean percent change in IPSS in the treatment arm is at least 30% improvement over the patient's pre-treatment baseline score.
Measured: Procedure to 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

9 Jun 2022Dec 2028

First posted11 Jan 2022
Study start9 Jun 2022
Primary completion15 Mar 2024
Study completionDec 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for BPH With Symptomatic Lower Urinary Tract SymptomsStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: Prospective, multi-center, randomized, double-blind, sham-controlled safety and effectiveness study
Masking: Double blind
Who is masked: Participant, Outcomes assessor
Enrolment: 221 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05186740
Sponsor's protocol ID: CIP-002
Acronym: ProVIDE
Status last verified: Jul 2026
First submitted: 23 Dec 2021
Last updated: 28 Jul 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: Yes
Individual data sharing: No

Publications

Kaplan SA, Parekattil SJ, Wu NZ, Mazzarella B, Trotter M, Freedman S, Lawindy S, Bukkapatnam R, Schwartz BF, Jones B, Sethi P, Jalkut M, Liu JS, Elterman D, Gheiler E, Gonzalez RR, Kaminetsky J, Motola JA, Te A, Chapple C, Lerner L, Lynch T. 12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia. J Urol. 2026 Apr;215(4):421-430. doi: 10.1097/JU.0000000000004896. Epub 2025 Dec 15.
PubMed 41396103

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
Evaluating the Clinical Efficacy of Thulio vs. Holmium Laser Enucleation of the Prostate
BPH With Symptomatic Lower Urinary Tract Symptoms, BPH With Urinary Obstruction
Not yet recruitingObservational study
ProVIDE Studies Post Exit Analysis
BPH With Symptomatic Lower Urinary Tract Symptoms
RecruitingObservational study
Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry
BPH (Benign Prostatic Hyperplasia)
Recruiting
Use of PuraStat Following Aquablation to Determine if There is Change in Hematuria & Probability of Same Day Discharge
BPH (Benign Prostatic Hyperplasia), BPH With Symptomatic Lower Urinary Tract Symptoms
Active, not recruiting
ProVIDE II Bridging Study
BPH With Symptomatic Lower Urinary Tract Symptoms

All BPH With Symptomatic Lower Urinary Tract Symptoms trials

Study at a glance

From the registry record, last updated by the sponsor on 28 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: The ProVee Urethral Expander System Clinical Study
ClinicalTrials.gov ID: NCT05186740
Acronym / sponsor ID: ProVIDE / CIP-002
Conditions: BPH With Symptomatic Lower Urinary Tract Symptoms
Keywords: BPH / LUTS
Study type: Interventional
Recruitment status: Active, not recruiting
Enrolment: 221 participants (actual)
Lead sponsor: ProVerum MedicalIndustry (pharma, biotech, devices)
Study start: 9 Jun 2022 (actual)
Primary completion: 15 Mar 2024 (actual)
Study completion: Dec 2028 (estimated)
First posted: 11 Jan 2022 (actual)
Results: Posted 1 Dec 2025

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, outcomes assessor)
Number of arms: 3
Model description: Prospective, multi-center, randomized, double-blind, sham-controlled safety and effectiveness study

Arm	Type	Receives
Device: The ProVee Urethral Expander System	Active comparator	Device: ProVee Urethral Expander SystemThe ProVee Urethral Expander System consists of two components: a nitinol Expander implant and a 19Fr Delivery System designed to allow the Expander to be deployed under direct vision for the treatment arm.
Sham: Ureteroscope and urethral access sheath	Sham comparator	Procedure: Urethral Access SheathAn ureteroscope housed within the inner lumen of an urethral access sheath will be used under direct vision for the Sham procedure.
Crossover ProVee Urethral Expander System	Other	Device: ProVee Urethral Expander SystemAll subjects shall be unblinded following the 3 month follow-up visit. Those subjects randomized to the Sham Arm will be given the opportunity to "crossover" to the ProVee Urethral Expander System.

Who may qualify

Ages: 45 years and older
Sex: Male only
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (5 listed)

Males > 45 years of age
IPSS of ≥ 13, IPSS V/S > 1 at baseline assessment
Prostate volume of ≥ 30 cc and ≤ 80 cc
Prostatic urethral L2 lengths ≥ 3.75cm by TRUS
Failed, intolerant, or subject choice to not take a medication regimen for the treatment of LUTS

Key exclusion criteria (44 listed)

Void volume <125 ml; Qmax > 12ml/s; PVR > 250 ml
Obstructive median lobe defined by EITHER (>10mm protrusion on sagittal mid-prostate plane as measured by TRUS) OR an obstructive median lobe seen on cystoscopy e.g., 'ball valve''
High bladder neck, with the absence of lateral lobe encroachment indicating a high likelihood of primary bladder neck obstruction
Anatomy that would prevent the apices of the ProVee from engaging with the lateral lobes e.g., high degree of bladder neck angulation such that the anterior bladder neck is not visible
Acute urinary retention

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
ProVee Urethral Expander SystemAlso: ProVee Expander, ProVeeProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.	Device	Crossover ProVee Urethral Expander System, Device: The ProVee Urethral Expander System
Urethral Access SheathThe Urethral Access Sheath is introduced into the prostatic urethra to simulate the placement of the ProVee Expander.	Procedure or surgery	Sham: Ureteroscope and urethral access sheath

Primary outcome

Safety: Adverse Events (Time Frame: Procedure to 12 Months)
Time frame: Procedure - 12 months
This includes the rate of device or procedure related serious adverse events through 12-months.
Safety: Number of Participants With Need for Urinary Catheterization (Time Frame: >7 Days Post Procedure)
Time frame: 7 days post treatment through to 12 months
The rate of extended post-operative urinary catheterization for inability to void among patients treated with the ProVee device.
Effectiveness: Number of Participants With Reduction in BPH Symptoms Compared to Sham (Time Frame: Procedure to 3 Months)
Time frame: Procedure to 3 months
The ProVee Treatment Group will be considered superior to the Sham Treatment Group when the mean 3-month improvement from baseline score for the IPSS symptom questionnaire demonstrates a minimum statistical margin of 25% compared to mean improvement from baseline for the Sham Treatment Group alone.
Effectiveness: Number of Participants With Symptoms Improvements (Time Frame: Procedure to 12 Months)
Time frame: Procedure to 12 months
The mean percent change in IPSS in the treatment arm is at least 30% improvement over the patient's pre-treatment baseline score.

Results and safety

Results posted to the registry on 1 Dec 2025, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Device: The ProVee Urethral Expander System	150	150
Sham: Ureteroscope and Urethral Access Sheath	71	71

Primary outcome: Safety: Adverse Events (Time Frame: Procedure to 12 Months)

Time frame: Procedure - 12 months. Count of participants. Unit: Participants

Measure	Device: The ProVee Urethral Expander System n = 150	Sham: Ureteroscope and Urethral Access Sheath n = 71	Crossover ProVee Urethral Expander System n = 64
Value	0	0	0

Population analysed: At 3 month follow-up visit, 64 subjects were crossed over from Sham (Uretheroscope and urethral access sheath) to Device (The ProVee Urethral Expander System)

Primary outcome: Safety: Number of Participants With Need for Urinary Catheterization (Time Frame: >7 Days Post Procedure)

Time frame: 7 days post treatment through to 12 months. Count of participants. Unit: Participants

Measure	Device: The ProVee Urethral Expander System n = 150	Sham: Ureteroscope and Urethral Access Sheath n = 71	Crossover ProVee Urethral Expander System n = 64
Value	0	0	0

Population analysed: At 3-month follow up, 64 subject were crossed over from Sham (Ureteroscope and Urethral Access Sheath) to Device (The ProVee Urethral Expander System).

Primary outcome: Effectiveness: Number of Participants With Reduction in BPH Symptoms Compared to Sham (Time Frame: Procedure to 3 Months)

Time frame: Procedure to 3 months. Count of participants. Unit: Participants

Measure	Device: The ProVee Urethral Expander System n = 150	Sham: Ureteroscope and Urethral Access Sheath n = 71	Crossover ProVee Urethral Expander System n = 64
Value	0	0	0

Population analysed: Following the 3 month follow up, 64 subjects were crossed over from sham (ureteroscope and urethral access sheath) to device (the ProVee ureteral expander system)

Primary outcome: Effectiveness: Number of Participants With Symptoms Improvements (Time Frame: Procedure to 12 Months)

Time frame: Procedure to 12 months. Count of participants. Unit: Participants

Measure	Device: The ProVee Urethral Expander System n = 150	Sham: Ureteroscope and Urethral Access Sheath n = 71	Crossover ProVee Urethral Expander System n = 64
Value	0	0	0

Population analysed: Following the 3 month follow up, 64 subjects from sham (ureteroscope and urethral access sheath) crossed over to device (the ProVee urethral expander system)

Adverse events

Time frame: All subjects are followed for 3 months until the co-primary effectiveness endpoints are evaluated. After their 3-month visit, all subjects are unblinded to their treatment assignment. Subjects assigned to the ProVee Device will continue to be followed up to 60 months post implantation. Following unblinding, subjects assigned to the control arm may (crossover to the active treatment). After being treated, Crossover Subjects will be followed using the same schedule used with the ProVee Device.. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Device: The ProVee Urethral Expander System	8 of 150 (5.3%)	1 of 150 (0.7%)	1 of 150
Sham: Ureteroscope and Urethral Access Sheath	0 of 71 (0%)	0 of 71 (0%)	0 of 71
Crossover ProVee Urethral Expander System	0 of 64 (0%)	0 of 64 (0%)	0 of 64

Limitations and caveats (from the sponsor): This Clinical Study Protocol and Statistical Analysis Plan has been redacted in accordance with the regulations at 42 CFR 11.48(a)(5). Note that the all cause mortality results, the CEC adjudicated that the death was related to a pre-existing condition. For the serious adverse events, no reported serious adverse events have been adjudicated by CEC as device or procedural related.

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 41396103Kaplan SA, Parekattil SJ, Wu NZ, Mazzarella B, Trotter M, Freedman S, Lawindy S, Bukkapatnam R, Schwartz BF, Jones B, Sethi P, Jalkut M, Liu JS, Elterman D, Gheiler E, Gonzalez RR, Kaminetsky J, Motola JA, Te A, Chapple C, Lerner L, Lynch T. 12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia. J Urol. 2026 Apr;215(4):421-430. doi: 10.1097/JU.0000000000004896. Epub 2025 Dec 15.
ProVerum WebsiteLink provided by the sponsor.
Individual participant dataSharing planned: No

Related trials for BPH With Symptomatic Lower Urinary Tract Symptoms

Recruiting
Evaluating the Clinical Efficacy of Thulio vs. Holmium Laser Enucleation of the Prostate
BPH With Symptomatic Lower Urinary Tract Symptoms, BPH With Urinary Obstruction
Not yet recruitingObservational study
ProVIDE Studies Post Exit Analysis
BPH With Symptomatic Lower Urinary Tract Symptoms
RecruitingObservational study
Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry
BPH (Benign Prostatic Hyperplasia)
Recruiting
Use of PuraStat Following Aquablation to Determine if There is Change in Hematuria & Probability of Same Day Discharge
BPH (Benign Prostatic Hyperplasia), BPH With Symptomatic Lower Urinary Tract Symptoms
Active, not recruiting
ProVIDE II Bridging Study
BPH With Symptomatic Lower Urinary Tract Symptoms

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

16 sites in 3 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing ProVee Urethral Expander System and Urethral Access Sheath in people with BPH With Symptomatic Lower Urinary Tract Symptoms, run by ProVerum Medical at 16 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 44 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 28 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 16 sites in United States, Canada, Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Dec 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety: Adverse Events (Time Frame: Procedure to 12 Months) (time frame: Procedure - 12 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05186740, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2026.